News Releases

Date Title and Summary Additional Formats
September 16, 2021 Ayala Pharmaceuticals Presents Preliminary Clinical Data from the Ongoing Phase 2 ACCURACY Trial and Announces Pre-Clinical Proof of Concept Data for Enhanced Activity of AL101 in Combination with Approved Cancer Therapies in ACC
- Posters presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2021 - Preliminary data showed meaningful clinical activity of AL101 6mg monotherapy with 70% disease control rate - AL101 was well tolerated with manageable side effects REHOVOT, Israel and WILMINGTON, Del.,
September 2, 2021 Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
REHOVOT, Israel and WILMINGTON, Del., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that
September 1, 2021 Ayala Pharmaceuticals to Present Clinical Data from Ongoing Phase 2 ACCURACY Trial and New Preclinical Results from Combination Study of AL101 at the European Society for Medical Oncology (ESMO) Virtual Congress 2021
REHOVOT, Israel and WILMINGTON, Del., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced
August 13, 2021 Ayala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
- Enrolled the First Patient in the Phase 2/3 Pivotal Trial of AL102 for the Treatment of Desmoid Tumors - Multiple Near-Term Milestones Across Clinical-Stage Pipeline - Updated ACCURACY Trial Data to Be Presented at ESMO 2021- REHOVOT, Israel and WILMINGTON, Del., Aug.
July 6, 2021 Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
REHOVOT, Israel & WILMINGTON, Del., July 06, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that
May 27, 2021 Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
REHOVOT, Israel and WILMINGTON, Del., May 27, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that
May 14, 2021 Ayala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
         - First Patient Dosed in Phase 1 AL102 Combination Trial with Novartis’ Anti-BCMA Agent for the Treatment of Multiple Myeloma - - On Track to Initiate AL102 Phase 2/3 Pivotal Trial for the Treatment of Desmoid Tumors in 1H21- - Multiple Near-Term Milestones Expected Across Clinical-Stage
April 21, 2021 Ayala Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of AL102 in Combination with BCMA Targeting Agent, WVT078, in Patients with relapsed/refractory Multiple Myeloma
REHOVOT, Israel and WILMINGTON, Del., April 21, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced the
March 25, 2021 Ayala Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Business Update
- Completed $25 Million Strategic Financing; Extending Cash Runway into 2023          - Accelerated Development of AL102 Desmoid Tumor Program into Phase 2/3 Pivotal Trial - On Track to Report Multiple Milestones in 2021 Across Clinical-Stage Pipeline REHOVOT, Israel and WILMINGTON, Del., March 25,
March 2, 2021 Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
REHOVOT, Israel and WILMINGTON, Del., March 02, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that
Displaying 1 - 10 of 15